Our webinars allow users to learn from experts and earn continuing education credits on industry topics, progress in research, services available, and more.
Professor Stockwell will discuss the discovery of ferroptosis, a novel model of regulated but non-apoptotic cell death. He will describe how some tumors are sensitized to ferroptosis and may...
In the past decade, we have witnessed an explosion in the availability of high-resolution structural information that sheds light on the binding of diverse classes of ligands to both soluble...
A panel of veteran biotech reporters will discuss hot topics in drug development. Expect a lively debate on emerging technologies, shifting dynamics on drug pricing, and the general health of...
This presentation will focus on NuMediis general approach towards the discovery of new therapeutic uses for existing drugs. While the business models for repurposing marketed drugs versus rep...
Heptares Therapeutics is a structure based drug discovery and development company which uses it StaR technology to enable X-ray structures, fragment screening and other biophysical techniques...
The ever-quickening pace of breathtaking advances in our understanding of disease biology has implicitly promised a profusion of drugs that will dramatically improve human health and well-bei...
The ever-quickening pace of breathtaking advances in our understanding of disease biology has implicitly promised a profusion of drugs that will dramatically improve human health and well-bei...
Target selection is arguably the most important decision in all drug discovery and development activities. No amount of great science can overcome the selection of the wrong target. The rapid...
Antibiotics are among the most important advances in the history of modern medicine. They turned often acutely fatal infections into treatable indications with radical cures. Antibiotics co...
Diseases caused by an excess of protein function can often be treated by small molecule inhibitors. In contrast, many diseases caused by missing proteins cannot be addressed with this classic...
Duchenne Muscular Dystrophy (DMD) is an X-linked genetic disease occurring in 1 in 3,500 births, and is uniformly fatal in boys. It is caused by any one of over 50 known mutations in the gen...
Transforming serious brain disease through cutting edge science, generating novel medicines that enable patients to overcome everyday challenges and achieve their full potential...
Since leaving Pfizer to go back to academia in 2007, Andrew Hopkins (University of Dundee, UK) has been a leading researcher in the search for new informatics and computational methods to imp...
Macrocycles offer a new structural class that has the potential to address challenging protein-protein interaction targets and still present attractive drug-like properties including cell mem...
Patients with chromosomal rearrangements resulting in fusion proteins are among the most responsive to published targeted therapy. For example, targeting of the EML4-ALK fusion in non-small c...
Late-stage drug attrition rates in oncology remain higher than in other therapeutic areas. To reduce attrition, it is critical to identify appropriate drug targets and pre-clinical models. Th...
The use of biomarkers for the stratification of populations for therapy is a concept that holds the potential to revolutionize clinical trial design, the economics of healthcare, and most imp...
Practicing Internist and vitamin D researcher Gregory A. Plotnikoff, MD, MTS, FACP, will review how new testing for 1,25-Dihydroxyvitamin D can enhance your clinical practice. Issues to be ...
In this webinar, we will describe a comprehensive approach for NGS-based marker discovery and the successful migration of these markers to targeted NGS assays using low-quality (FFPE) and low...
Colloidal nanoparticles have become important materials in biomedicine, catalysis, and optoelectronics. Their unique nanoscale properties stem from their size (particularly of the i...
Rare disorder analysis has been facilitated by the declining cost of sequencing. Despite numerous success stories the underlying cause remains unexplained in >50% cases, emphasizing the ne...
When whole genome and whole exome sequencing are introduced into health care, and offered directly to consumers in commercial settings, the landscape of genetic testing will drastically chang...
DNASTAR offers an integrated suite of software for assembling and analyzing sequence data from all major next-generation sequencing platforms. DNASTAR software supports a variety of key workf...